Deva Holding AS - Asset Resilience Ratio

Latest as of September 2025: 2.10%

Deva Holding AS (DEVA) has an Asset Resilience Ratio of 2.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Deva Holding AS's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

TL745.77 Million
≈ $16.70 Million USD Cash + Short-term Investments

Total Assets

TL35.50 Billion
≈ $795.16 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how Deva Holding AS's Asset Resilience Ratio has changed over time. See Deva Holding AS net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Deva Holding AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DEVA stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents TL0.00 0%
Short-term Investments TL745.77 Million 2.1%
Total Liquid Assets TL745.77 Million 2.10%

Asset Resilience Insights

  • Limited Liquidity: Deva Holding AS maintains only 2.10% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Deva Holding AS Industry Peers by Asset Resilience Ratio

Compare Deva Holding AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for Deva Holding AS (2005–2024)

The table below shows the annual Asset Resilience Ratio data for Deva Holding AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.06% TL1.21 Billion
≈ $27.01 Million
TL29.73 Billion
≈ $665.86 Million
-5.05pp
2023-12-31 9.11% TL2.95 Billion
≈ $66.10 Million
TL32.40 Billion
≈ $725.77 Million
+0.59pp
2022-12-31 8.52% TL734.62 Million
≈ $16.45 Million
TL8.62 Billion
≈ $193.16 Million
-4.19pp
2019-12-31 12.70% TL269.26 Million
≈ $6.03 Million
TL2.12 Billion
≈ $47.47 Million
+12.70pp
2018-12-31 0.01% TL86.10K
≈ $1.93K
TL1.67 Billion
≈ $37.37 Million
-0.01pp
2008-12-31 0.01% TL73.00K
≈ $1.64K
TL489.79 Million
≈ $10.97 Million
-0.05pp
2006-12-31 0.06% TL177.00K
≈ $3.96K
TL290.88 Million
≈ $6.52 Million
+0.05pp
2005-12-31 0.01% TL30.00K
≈ $671.92
TL273.18 Million
≈ $6.12 Million
--
pp = percentage points

About Deva Holding AS

IS:DEVA Turkey Drug Manufacturers - Specialty & Generic
Market Cap
$307.77 Million
TL13.74 Billion TRY
Market Cap Rank
#14807 Global
#150 in Turkey
Share Price
TL68.70
Change (1 day)
+1.70%
52-Week Range
TL52.35 - TL80.65
All Time High
TL102.39
About

Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more